Wakamoto Pharmaceutical Co.,Ltd.

Tokyo Stock Exchange 4512.T

Wakamoto Pharmaceutical Co.,Ltd. Price to Earnings Ratio (P/E) on January 28, 2025: 70.03

Wakamoto Pharmaceutical Co.,Ltd. Price to Earnings Ratio (P/E) is 70.03 on January 28, 2025, a 44.97% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Wakamoto Pharmaceutical Co.,Ltd. 52-week high Price to Earnings Ratio (P/E) is 100.72 on September 24, 2024, which is 43.82% above the current Price to Earnings Ratio (P/E).
Wakamoto Pharmaceutical Co.,Ltd. 52-week low Price to Earnings Ratio (P/E) is 44.60 on March 05, 2024, which is -36.32% below the current Price to Earnings Ratio (P/E).
Wakamoto Pharmaceutical Co.,Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 71.39.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Tokyo Stock Exchange: 4512.T

Wakamoto Pharmaceutical Co.,Ltd.

CEO	Mr. Arata Igarashi
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	2-2-2, Nihonbashi Honcho
Employees	403
Sector	Health Care
Industries Pharmaceuticals

Description

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years